Lyudmila S. Koroleva

Dr. Lyudmila S. Koroleva

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Polymers
Verified
Journal Article
Open access
PDF file
LALarisa Antonova
Larisa Antonova
VSVladimir N. Sil’nikov
Vladimir N. Sil’nikov
VSViktoriia Sevostianova
Viktoriia Sevostianova
Arseniy E YuzhalinArseniy E Yuzhalin
Arseniy E Yuzhalin
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
LBLeonid Barbarash
Leonid Barbarash
Modification with Arg-Gly-Asp (RGD) peptides is a promising approach to improve biocompatibility of small-calibre vascular grafts but it is unknown how different RGD sequence composition impacts graft performance. Here we manufactured 1.5 mm poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(ε-caprolactone) grafts modified by distinct linear or cyclic RGD peptides immobilized by short or long amine linker arms. Modified vascular prostheses were tested in vitro to assess their mechanical properties, hemocompatibility, thrombogenicity and endothelialisation. We also implanted these grafts into rat abdominal aortas with the following histological examination at 1 and 3 months to evaluate their primary patency, cellular composition and detect possible calcification. Our results demonstrated that all modes of RGD modification reduce ultimate tensile strength of the grafts. Modification of prostheses does not cause haemolysis upon the contact with modified grafts, yet all the RGD-treated grafts display a tendency to promote platelet aggregation in comparison with unmodified counterparts. In vivo findings identify that cyclic Arg-Gly-Asp-Phe-Lys peptide in combination with trioxa-1,13-tridecanediamine linker group substantially improve graft biocompatibility. To conclude, here we for the first time compared synthetic small-diameter vascular prostheses with different modes of RGD modification. We suggest our graft modification regimen as enhancing graft performance and thus recommend it for future use in tissue engineering.

29 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TPTatyana Popova
Tatyana Popova
MDMaya A. Dymova
Maya A. Dymova
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
OZOlga Zakharova
Olga Zakharova
VLVladimir Lisitskiy
Vladimir Lisitskiy
TGTatyana S. Godovikova
Tatyana S. Godovikova
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-‘click’ chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.

30 August 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
AGAlina Grigor'eva
Alina Grigor'eva
ABAlevtina V. Bardasheva
Alevtina V. Bardasheva
ERElena Ryabova
Elena Ryabova
ATAnastasiya V. Tupitsyna
Anastasiya V. Tupitsyna
Danila ZadvornykhDanila Zadvornykh
Danila Zadvornykh
ERElena Ryabchikova
Elena Ryabchikova
The purposeful development of synthetic antibacterial compounds requires an understanding of the relationship between effects of compounds and their chemical structure. This knowledge can be obtained by studying changes in bacteria ultrastructure under the action of antibacterial compounds of a certain chemical structure. Our study was aimed at examination of ultrastructural changes in S. aureus cells caused by polycationic amphiphile based on 1,4‒diazabicyclo[2.2.2]octane (DL412), ciprofloxacin and their hybrid (DL5Cip6); the samples were incubated for 15 and 45 min. DL412 first directly interacted with bacterial cell wall, damaging it, then penetrated into the cell and disrupted cytoplasm. Ciprofloxacin penetrated into cell without visually damaging the cell wall, but altered the cell membrane and cytoplasm, and inhibited the division of bacteria. The ultrastructural characteristics of S. aureus cells damaged by the hybrid clearly differed from those under ciprofloxacin or DL412 action. Signs associated with ciprofloxacin predominated in cell damage patterns from the hybrid. We studied the effect of ciprofloxacin, DL412 and their hybrid on S. aureus biofilm morphology using paraffin sections. Clear differences in compound effects on S. aureus biofilm (45 min incubation) were observed. The results obtained allow us to recommend this simple and cheap approach for the initial assessment of antibiofilm properties of synthesized compounds.

1 November 2005 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
ADA. A. Donina
A. A. Donina
NTN. V. Tamkovich
N. V. Tamkovich
NKN. A. Kovalev
N. A. Kovalev
MZM. A. Zenkova
M. A. Zenkova
VSV. N. Sil’nikov
V. N. Sil’nikov

1 February 2007 in Protein & Peptide Letters
Verified
Journal Article
Closed access
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
ISInna Yu. Serpokrylova
Inna Yu. Serpokrylova
VVValentin V. Vlassov
Valentin V. Vlassov
VSVladimir N. Silnikov
Vladimir N. Silnikov
Abstract: The present review is aimed at giving a general overview of our results in the field of designing and synthesizing simple peptide-like molecules that mimic structural and functional aspects of natural ribonucleases, as well as designing oligonucleotide-based artificial ribonucleases.

1 September 2016 in Antiviral Research
Verified
Journal Article
Closed access
AFAntonina A. Fedorova
Antonina A. Fedorova
EGElena P. Goncharova
Elena P. Goncharova
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
EBEkatherina A. Burakova
Ekatherina A. Burakova
ERElena Ryabchikova
Elena Ryabchikova
MZMarina Zenkova
Marina Zenkova